Intracavitary doxorubicin hydrochloride treatment for carcinoma in situ of the urinary bladder. A comparative study of two therapy regimens.
In two subsequent, non-randomized groups of 9 patients with carcinoma in situ doxorubicin hydrochloride was applied intravesically. The dosage used was 40 and 80 mg. Tumour remission was obtained in 6 patients per group. The tumour grade might be of prognostic value. Cold cup random biopsies are warranted in the follow-up.